[go: up one dir, main page]

DE69733462D1 - Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen - Google Patents

Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen

Info

Publication number
DE69733462D1
DE69733462D1 DE69733462T DE69733462T DE69733462D1 DE 69733462 D1 DE69733462 D1 DE 69733462D1 DE 69733462 T DE69733462 T DE 69733462T DE 69733462 T DE69733462 T DE 69733462T DE 69733462 D1 DE69733462 D1 DE 69733462D1
Authority
DE
Germany
Prior art keywords
mutants
elastase
mutant
cell migration
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733462T
Other languages
English (en)
Other versions
DE69733462T2 (de
Inventor
A Lawrence
P Stefansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
American National Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American National Red Cross filed Critical American National Red Cross
Application granted granted Critical
Publication of DE69733462D1 publication Critical patent/DE69733462D1/de
Publication of DE69733462T2 publication Critical patent/DE69733462T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69733462T 1996-04-12 1997-04-11 Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen Expired - Lifetime DE69733462T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1529996P 1996-04-12 1996-04-12
US15299P 1996-04-12
PCT/US1997/006071 WO1997039028A1 (en) 1996-04-12 1997-04-11 Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof

Publications (2)

Publication Number Publication Date
DE69733462D1 true DE69733462D1 (de) 2005-07-14
DE69733462T2 DE69733462T2 (de) 2006-03-23

Family

ID=21770626

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733462T Expired - Lifetime DE69733462T2 (de) 1996-04-12 1997-04-11 Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen

Country Status (7)

Country Link
US (1) US6103498A (de)
EP (1) EP0850252B1 (de)
AT (1) ATE297466T1 (de)
AU (1) AU726406B2 (de)
CA (1) CA2233670C (de)
DE (1) DE69733462T2 (de)
WO (1) WO1997039028A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2000040227A2 (en) 1999-01-05 2000-07-13 University Of Utah Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2000065349A2 (en) * 1999-04-28 2000-11-02 Cardiogenics Inc. Method for determining plasminogen activator inhibitor
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
US20040063605A1 (en) * 2000-08-02 2004-04-01 Jesper Eugen-Olsen Composition and method for the treatment or prevention of hiv infection
DE10048091A1 (de) * 2000-09-28 2002-04-25 Ernst Bayer Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor
AT500019B1 (de) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen
US7264953B2 (en) * 2001-07-18 2007-09-04 American National Red Cross Mutant proteinase-inhibitors and uses thereof
AU2002352115A1 (en) * 2001-11-27 2003-06-10 Bayer Aktiengesellschaft Polynucleotides encoding nexin-related serine protease inhibitor
US20060084056A1 (en) * 2002-02-13 2006-04-20 Nadia Harbeck Methods for selecting treatment regimens and predicting outcomes in cancer patients
DE60325946D1 (de) * 2002-03-04 2009-03-12 Univ Toledo Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren
WO2003083104A1 (en) * 2002-03-25 2003-10-09 Molecular Innovations Method for making purified plasminogen activator-inhibitor type 1 (pai-1) and purified pai-1 made thereform
US20060121591A1 (en) * 2002-07-18 2006-06-08 American National Red Cross Mutant proteinase-inhibitors and uses thereof
US6788072B2 (en) * 2003-01-13 2004-09-07 Delphi Technologies, Inc. Apparatus and method for sensing particle accumulation in a medium
US7375076B2 (en) * 2003-05-20 2008-05-20 The Regents Of The University Of Michigan Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
US20050244893A1 (en) * 2004-04-16 2005-11-03 Wyeth Novel method for determination of plasminogen activator inhibitor
IL163453A0 (en) * 2004-08-10 2009-02-11 Yeda Res & Dev Enzyme inhibitor in leukemia
US8795730B2 (en) * 2006-01-31 2014-08-05 David John Vachon Compositions and methods for promoting the healing of tissue of multicellular organisms
US8969295B2 (en) 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
US8211858B2 (en) 2007-04-27 2012-07-03 The University Of Toledo Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
WO2009045412A2 (en) * 2007-10-01 2009-04-09 American Diagnostica, Inc. Methods of treatment using modified plasminogen activator inhibitor type-1 molecules
WO2015026494A2 (en) * 2013-08-20 2015-02-26 Trustees Of Dartmouth College Methods for treating tissue fibrosis
AU2020349353A1 (en) 2019-09-17 2022-04-14 Duke University Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
WO2021102176A2 (en) * 2019-11-21 2021-05-27 The Regents Of The University Of Michigan Polypeptide inhibitors of neutrophil elastase activity and uses thereof
EP4252850A3 (de) 2020-04-16 2023-11-15 Mereo Biopharma 4 Limited Methoden beinhaltend neutrophile elastase inhibitor alvelestat zur behandlung von atemwegserkrankung aufgrund von alpha-1 antitrypsin mangel
KR20240090272A (ko) 2021-10-20 2024-06-21 메레오 바이오파마 4 리미티드 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제

Also Published As

Publication number Publication date
WO1997039028A1 (en) 1997-10-23
EP0850252A4 (de) 2001-04-11
DE69733462T2 (de) 2006-03-23
AU2665397A (en) 1997-11-07
CA2233670A1 (en) 1997-10-23
EP0850252B1 (de) 2005-06-08
US6103498A (en) 2000-08-15
ATE297466T1 (de) 2005-06-15
EP0850252A1 (de) 1998-07-01
AU726406B2 (en) 2000-11-09
CA2233670C (en) 2012-01-31

Similar Documents

Publication Publication Date Title
DE69733462D1 (de) Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen
Van Damme et al. Induction of monocyte chemotactic proteins MCP-1 and MCP-2 in human fibroblasts and leukocytes by cytokines and cytokine inducers. Chemical synthesis of MCP-2 and development of a specific RIA.
Van Deerlin et al. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
Shalak et al. The EMAPII cytokine is released from the mammalian multisynthetase complex after cleavage of its p43/proEMAPII component
Huang et al. Expression and purification of functional human α‐1‐antitrypsin from cultured plant cells
US5401651A (en) DNA encoding ENA-78, a neutrophil activating factor
Proost et al. Human and bovine granulocyte chemotactic protein-2: complete amino acid sequence and functional characterization as chemokines
Blinder et al. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
Kuhn et al. Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor.
Hogg Thrombospondin 1 as an enzyme inhibitor
Perlmutter et al. Distinct and additive effects of elastase and endotoxin on expression of alpha 1 proteinase inhibitor in mononuclear phagocytes.
Stone et al. Localization of the heparin-binding site of glia-derived nexin/protease nexin-1 by site-directed mutagenesis
JP3226215B2 (ja) ヒト抗トロンビン３の変異体
Zhu et al. Oxidation‐resistant and thermostable forms of alpha‐1 antitrypsin from Escherichia coli inclusion bodies
WO1995011260A1 (fr) Procede de preparation d'un concentre d'inter-alpha-trypsine inhibiteur a usage therapeutique et concentre obtenu
ATE421528T1 (de) Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren
Owen et al. Antithrombin Glasgow, 393 Arg to His: a P1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity
AU610500B2 (en) Variants of alpha1-antitrypsin which are useful, in particular, as kallikrein inhibitors
MARUYAMA Thrombomodulin, An Endothelial Anticoagulant: Its Structure, Function and Expression: ROLES OF VASCULAR ENDOTHELIUM IN REGULATION OF CARDIOVASCULAR SYSTEM
Ocampo‐Gallego et al. Human neutrophil elastase inhibitors: Classification, biological‐synthetic sources and their relevance in related diseases
ATE408622T1 (de) Urocortinproteine und deren verwendungen
Noguchi et al. Identification and partial purification of a novel tumor-derived protein that induces tissue factor on cultured human endothelial cells
WO2004005475A3 (en) Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
US5585474A (en) DNA encoding protein possessing metastasis-inhibitory activity
BR0009980A (pt) Polinucleotìdeos de npr1 de milho e métodos de uso

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ANN, US